Pediatric Issues
5. Once an alternate regimen has been identified in adults, should we require identical PK profiles in children (i.e., all exposure measures equivalent) or only equivalent critical parameters (i.e., AUC or Cmin)?
Does this apply to all drugs and all pediatric sub-populations or are there some situations in which more clinical/virologic data will be necessary?